Detalhe da pesquisa
1.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood
; 140(10): 1104-1118, 2022 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35878001
2.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2499-2512, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041225
3.
Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood
; 132(23): 2484-2494, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30275109
4.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2513-2514, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37154851
5.
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Front Immunol
; 12: 608625, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33790890
6.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia
; 35(8): 2243-2257, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414484
7.
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Mol Cancer Ther
; 19(9): 1875-1888, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518207